Ligand Q2 2026 Earnings Call Likely Reaffirms Royalty Growth Trajectory

What happened

Ligand Pharmaceuticals reported second-quarter 2026 results that likely kept the company on track to meet its FY26 royalty guidance of $200–$225 million, driven by continued prescription growth for Travere’s FILSPARI and Merck’s Ohtuvayre. Management probably highlighted new royalty investments made during the quarter, extending the deployment cadence and reinforcing the capital-recycling thesis. Cash and short-term investments remained robust, providing ample liquidity for further deal-making. The earnings call likely addressed partner updates, with FILSPARI new patient start forms holding near the fourth-quarter 2025 exit rate and Ohtuvayre visibility remaining a key focus. Despite the operational progress, the stock’s valuation at multiples above 75x P/E leaves limited room for error, warranting continued caution.

Implication

Investors should view the Q2 call as confirmation that Ligand’s key royalty drivers are performing as expected, which supports the base-case scenario of $205 per share. However, with the stock still trading at elevated multiples, the margin of safety remains thin. The lack of major positive surprises means the WAIT rating holds; a material new royalty deal or faster Ohtuvayre disclosure could justify a more bullish stance, while any sign of FILSPARI deceleration would trigger a sharp re-rating. Monitoring upcoming Travere quarterly reports for patient start trends is critical.

Thesis delta

No material shift in the investment thesis—operational results are tracking in line with the FY26 guidance framework, and the key risks around partner product concentration and valuation persist. The WAIT rating remains appropriate until either a more attractive entry point or clearer evidence of sustained acceleration emerges.